Search Result

Results for "

CDK9 activity

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (81) Amyloid-β (1) Androgen Receptor (1) Apoptosis (32) Atg8/LC3 (1) Aurora Kinase (1) Autophagy (2) Bcl-2 Family (5) BCL6 (1) Biochemical Assay Reagents (1) c-Myc (6) Casein Kinase (1) Caspase (1) Cholinesterase (ChE) (1) COX (1) DNA/RNA Synthesis (6) Dopamine Transporter (1) Drug Isomer (2) E3 Ligase Ligand-Linker Conjugates (1) EGFR (5) Epigenetic Reader Domain (1) ERK (1) FLT3 (2) GSK-3 (4) HDAC (2) Histone Methyltransferase (1) HIV (2) IAP (1) IRAK (1) JAK (3) Ligands for Target Protein for PROTAC (3) MEK (2) Molecular Glues (1) PARP (1) PROTACs (6) Reactive Oxygen Species (ROS) (1) Reference Standards (4) SARS-CoV (2) Target Protein Ligand-Linker Conjugates (1) Virus Protease (1)
By Research Areas:	Cancer (81) Infection (4) Inflammation/Immunology (4) Neurological Disease (2)

By Targets:

CDK (81)

Amyloid-β (1)

Androgen Receptor (1)

Apoptosis (32)

Atg8/LC3 (1)

Aurora Kinase (1)

Autophagy (2)

Bcl-2 Family (5)

BCL6 (1)

Biochemical Assay Reagents (1)

c-Myc (6)

Casein Kinase (1)

Caspase (1)

Cholinesterase (ChE) (1)

COX (1)

DNA/RNA Synthesis (6)

Dopamine Transporter (1)

Drug Isomer (2)

E3 Ligase Ligand-Linker Conjugates (1)

EGFR (5)

Epigenetic Reader Domain (1)

ERK (1)

FLT3 (2)

GSK-3 (4)

HDAC (2)

Histone Methyltransferase (1)

HIV (2)

IAP (1)

IRAK (1)

JAK (3)

Ligands for Target Protein for PROTAC (3)

MEK (2)

Molecular Glues (1)

PARP (1)

PROTACs (6)

Reactive Oxygen Species (ROS) (1)

Reference Standards (4)

SARS-CoV (2)

Target Protein Ligand-Linker Conjugates (1)

Virus Protease (1)

By Research Areas:

Cancer (81)

Infection (4)

Inflammation/Immunology (4)

Neurological Disease (2)

Targets Recommended: CDK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-138293

SY-5609 5+ Cited Publications CDK7-IN-3	CDK Apoptosis	Cancer
SY-5609 (CDK7-IN-3) is an orally active, highly selective, noncovalent *CDK7* inhibitor with a K_D of 0.065 nM. SY-5609 shows poor inhibition on CDK2 (K_i=2600 nM), CDK9 (K_i=960 nM), CDK12 (K_i=870 nM). SY-5609 induces apoptosis in tumor cells and has antitumor activity .

HY-10012

AZD-5438 10+ Cited Publications	CDK	Cancer
AZD-5438 is a potent *CDK1, CDK2, and CDK9* inhibitor, with IC₅₀s of 16 nM, 6 nM, and 20 nM in cell-free assays, respectively. AZD-5438 shows less inhibition activity against GSK3β, CDK5 and CDK6 .

HY-12214A

NVP-2 Maximum Cited Publications 41 Publications Verification	CDK Apoptosis	Cancer
NVP-2 is a potent and selective ATP-competitive cyclin dependent kinase 9 (CDK9) probe, inhibits CDK9/CycT activity with an IC₅₀ of 0.514 nM. NVP-2 displays inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases with IC₅₀ values of 0.584 μM, 0.706 μM, and 0.605 μM, respectively. NVP-2 induces cell apoptosis.

HY-137478

KB-0742 3 Publications Verification	CDK	Cancer
KB-0742 is a potent, selective and orally active *CDK9* inhibitor with an IC₅₀ of 6 nM for CDK9/cyclin T1. KB-0742 is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 has potent anti-tumor activity .

HY-173523

KI-CDK9d-32	PROTACs CDK c-Myc	Cancer
KI-CDK9d-32 is a highly selective and potent *CDK9* PROTAC degrader (DC₅₀: 0.89 nM). KI-CDK9d-32 promotes the ubiquitination and degradation of CDK9. KI-CDK9d-32 inhibits the MYC pathway and disrupts nucleolar homeostasis. KI-CDK9d-32 exhibits anticancer activity against acute lymphoblastic leukemia and pancreatic cancer. (Pink: CDK9 ligand (HY-153718); Blue: E3 ligase CRBN ligand (HY-163233); Black: Linker (HY-W011657); E3 ligase CRBN ligand-linker conjugate (HY-173525)) .

HY-103019A

(±)-Enitociclib (±)-BAY-1251152; (±)-VIP152	CDK Apoptosis DNA/RNA Synthesis	Cancer
(±)-Enitociclib ((±)-BAY-1251152) is the racemic mixture of Enitociclib (HY-103019E). Enitociclib is a selective *CDK9* inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC ⁺ lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies .

HY-15504A

RGB-286638 free base 3 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a *CDK* inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and *p35-CDK5* with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-111388A

Romaciclib monohydrochloride 5+ Cited Publications SEL120-34A monohydrochloride	CDK	Cancer
SEL120-34A monohydrochloride is an ATP-competitive and selective *CDK8* inhibitor, inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC₅₀s of 4.4 nM and 10.4 nM, respectively, with a K_d of 3 nM for CDK8. SEL120-34A monohydrochloride weakly inhibits CDK9 (calculated IC₅₀=1070 nM), but shows no obvious activity against CDK1, 2, 4, 6, 5, 7. SEL120-34A monohydrochloride inhibits phosphorylation of STAT1 S727 and STAT5 S726 . Has anti-tumor activity .

HY-15504

RGB-286638 3 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a *CDK* inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and *p35-CDK5* with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-15815

Bromosporine 5 Publications Verification	Epigenetic Reader Domain Apoptosis CDK HIV	Cancer
Bromosporine, a chemical probe, is a potent BET inhibitor with an IC₅₀ value of 2.1 μM for PCAF. Bromosporine can arrest cell cycle and induce apoptosis in cancer cells. Bromosporine exhibits excellent antitumor activity in xenograft mice model when combined with 5-Fluorouracil (HY-90006). Bromosporine can increase *CDK9* T-loop phosphorylation in HIV-1 latency models, resulting the protection of reactivate HIV-1 replication from latency. Bromosporine can be used to research colorectal cancer, acute myeloid leukemia (AML) and AIDS .

HY-137478A

KB-0742 dihydrochloride 3 Publications Verification	CDK	Cancer
KB-0742 dihydrochloride is a potent, selective and orally active *CDK9* inhibitor with an IC₅₀ of 6 nM for CDK9/cyclin T1. KB-0742 dihydrochloride is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 dihydrochloride has potent anti-tumor activity .

HY-162706

BSJ-5-63 1 Publications Verification	PROTACs CDK	Cancer
BSJ-5-63 is a potent *CDK12, CDK7, CDK9* PROTAC degrader. BSJ-5-63 BSJ-5-63 decreases the protein expression of CDK12, CDK7, CDK9, RNAPII, Cyclin K. BSJ-5-63 decreases the mRNA expression of BRCA1, BRCA2. BSJ-5-63 shows anticancer activity and has the potential for the research of prostate cancer (Pink: ligand for target protein (HY-150948); black: linker (HY-W140827); Blue: E3 ligase ligand (HY-112078)) .

HY-16559

Riviciclib hydrochloride 3 Publications Verification P276-00	CDK Apoptosis	Cancer
Riviciclib hydrochloride (P276-00) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits *CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB* with IC₅₀s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib hydrochloride (P276-00) shows antitumor activity on cisplatin-resistant cells .

HY-100429

CAN508 1 Publications Verification	CDK	Cancer
CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC₅₀ of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity .

HY-103019B

(-)-Enitociclib 2 Publications Verification (R)-Enitociclib; (-)-BAY-1251152; (-)-VIP152	Drug Isomer CDK Apoptosis DNA/RNA Synthesis	Cancer
(-)-Enitociclib ((R)-Enitociclib) is an enantiomer of Enitociclib (HY-103019E) with an optical rotation of (-). Enitociclib is a selective *CDK9* inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC ⁺ lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies .

HY-176142

YX0798	CDK c-Myc Apoptosis Bcl-2 Family	Cancer
YX0798 is a selective and orally active *CDK9* inhibitor (K_d: 0.28 nM). YX0798 downregulates the oncoprotein c-MYC and pro-survival protein MCL-1. YX0798 disrupts the cell cycle and results in transcriptomic reprogramming, eventually leading to cell apoptosis. YX0798 has antitumor activity .

HY-178861

dCDK9-202	PROTACs CDK Caspase PARP Apoptosis	Cancer
dCDK9-202 a potent CDK9 PROTAC degrader with an DC₅₀ value of 3.5 nM. dCDK9-202 exhibits broad-spectrum anti-tumor activity and extensively disrupts the oncogenic transcriptome. dCDK9-202 can activate Caspase-3/7, increase the level of cleaved PARP, and directly induce apoptosis of tumor cells. dCDK9-202 effectively inhibits TC-71 tumor growth without any signs of toxicity in mice. dCDK9-202 can be used for the study of EGFR-driven cancers such as sarcoma (Pink: CDK9 ligand (HY-178862); Blue: CRBN ligand (HY-W248665); Black: Linker (HY-N8015)) .

HY-151071

TMX-3013	Ligands for Target Protein for PROTAC CDK	Cancer
TMX-3013 is a *CDK* inhibitor capable of inhibiting the activity of CDK1, CDK2, CDK4, CDK5, and CDK6, with IC₅₀ values of 0.9 nM, <0.5 nM, 24.5 nM, 0.5 nM, and 15.6 nM, respectively. TMX-3013 can be used as a target protein ligand, conjugated with the PROTAC linker and the CRBN ligand Thalidomide (HY-14658) for the synthesis of PROTAC TMX-2138 (HY-164906). TMX-3013 can also act as an effector ligand, binding to target proteins HaloTag or FKBP, and can be used in the synthesis of regulated induced proximity targeting chimeras (RIPTACs) .

HY-123955

Casein Kinase inhibitor A86	Casein Kinase CDK Apoptosis	Cancer
Casein Kinase inhibitor A86 is a potent and orally active casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A86 also inhibits of CDK7 (TFIIH) and CDK9 (P-TEFb). Casein Kinase inhibitor A861 induces leukemia cell apoptosis, and has potent anti-leukemic activities .

HY-161724

TFEB activator 2	Amyloid-β Dopamine Transporter CDK Autophagy	Neurological Disease
TFEB activator 2 is an orally active compound that can cross the blood-brain barrier. TFEB activator 2 can bind to the dopamine transporter (DAT). TFEB activator 2 promotes TFEB nuclear translocation and lysosome biogenesis by targeting the *DAT-CDK9-TFEB* pathway. TFEB activator 2 has neuroprotective activity and can be used in the research of Alzheimer's disease and other diseases .

HY-155218

TMX-2172	PROTACs CDK	Cancer
TMX-2172 is a selective bivalent cereblon-recruiting PROTAC-based dual *CDK2* and *CDK5* degrader with IC₅₀ values of 6.5 nM and 6.8 nM, respectively. TMX-2172 shows selectivity for CDK2 and CDK5 over other cell cycle CDKs (CDK1, CDK4, and CDK6) and transcriptional CDKs (CDK7 and CDK9). TMX-2172 inhibits CDK2/CDK5 enzymatic activity, induces their proteasomal degradation, reduces ASCL1 protein levels and half-life, induces cancer cell death, and exerts antiproliferative effects. TMX-2172 can be used for the research of ovarian cancer and small cell lung cancer .

HY-119715

AG-012986	CDK Apoptosis	Inflammation/Immunology Cancer
AG-012986 is a pan-CDK inhibitor with K_i values of 44 nM (CDK1), 9.2 nM (CDK4), 94 nM (CDK2), and IC50 values of 22 nM (CDK5), 4 nM (CDK9). AG-012986 causes apoptosis of T-cells by targeting upstream kinases in the p38 Mitogen-activated protein kinase (MAPK) pathway and impairing cellular survival. AG-012986 induces cell cycle arrest, retinoblastoma protein hypophosphorylation, and reduces K_i-67 expression. AG-012986 exerts antiproliferative activity in tumor cells, demonstrates antitumor efficacy in human xenograft models, and causes retinal and peripheral neurotoxicity, plus immune cell toxicity. AG-012986 can be used for the research of colon carcinoma, non-small cell lung carcinoma, lung carcinoma, breast carcinoma, ovarian tumor, pancreatic carcinoma, osteosarcoma, lymphoma, leukemia, retinotoxicity .

HY-156084

LL-K9-3	CDK PROTACs Apoptosis c-Myc	Cancer
LL-K9-3 is a potent small-molecule degrader of CDK9-cyclin T1. LL-K9-3 has anti-proliferative and pro-apoptotic activities and suppresses downstream signaling of CDK9 and AR. Moreover, LL-K9-3 inhibits AR and Myc-driven oncogenic transcriptional programs .

HY-169245

CDK-TCIP2	CDK BCL6	Cancer
DK-TCIP2, linking inhibitor of *CDK9* SNS-032 (HY-10008) with ligands of BCL6 BI-3812 (HY-111381), is a anticancer agent. DK-TCIP2 shows anticancer activity in vivo and in vitro and can be used for study of lymphoma cancer .

HY-115714

CDK9-IN-12	CDK	Cancer
CDK9-IN-12 displays the optimal *CDK9* inhibitory activity with an IC₅₀ value of 5.41 nM.

HY-176165

CDK9/EZH2-IN-1	CDK Histone Methyltransferase	Cancer
CDK9/EZH2-IN-1 (Compound D16) is a *CDK9/EZH2* dual-target inhibitor (IC₅₀: 83.9/108.6 nM). CDK9/EZH2-IN-1 induces apoptosis and DNA double-strand breaks (DSBs). CDK9/EZH2-IN-1 inhibits the proliferation activity of MKN45, MDA-MB-453 and SW620 cancer cells (IC₅₀ values are 136.3, 171.3 and 315.7 nM, respectively) .

HY-126251

CDK9-IN-7	CDK Apoptosis	Cancer
CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC₅₀=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC .

HY-100950

ABC1183	GSK-3 CDK	Inflammation/Immunology Cancer
ABC1183 is an orally active selective dual GSK3 and *CDK9* inhibitor. ABC1183 inhibits GSK3β, GSK3α and CDK9/cyclin T1 with the IC₅₀ values of 657 nM, 327 nM and 321 nM, respectively. ABC1183 has anti-inflammatory and anti-tumor activities .

HY-201330

GDC-4198 RGT-419B	CDK	Cancer
GDC-4198 (RGT-419B) is an orally active *CDK4/2* inhibitor with desired degrees of selectivity against kinases such as CDK6, CDK9 and GSK3β. GDC-4198 inhibits the activity of cyclin-CDK complexes, blocks phosphorylation of the retinoblastoma protein (pRb), arresting the cell cycle transition from G1 to S phase. GDC-4198 is promising for research of cancers, such as breast cancer (especially hormone receptor-positive, HER2-negative type), lung cancer, and colorectal cancer .

HY-151984

CDK9-IN-22	CDK	Cancer
CDK9-IN-22 is a potent *CDK9* inhibitor with IC₅₀s of 10.4, 876.2 nM for CDK9, CDK, respectively. CDK9-IN-22 induces apoptosis and cell cycle arrests at G2/M phase. CDK9-IN-22 decreases the expression of p-RNAPII (S2) and CDK9 protein. CDK9-IN-22 shows antiproliferative and aiti-tumor activity .

HY-130001

CDK9-IN-9	CDK	Cancer
CDK9-IN-9 (example 2) is a potent and selective *CDK9* inhibitor with an IC₅₀ of 1.8 nM. CDK9-IN-9 inhibits CDK2 with an IC₅₀ of 155 nM. CDK9-IN-9 has anti-cancer activity .

HY-176736

CDK9-IN-40	CDK Apoptosis	Cancer
CDK9-IN-40 is a potent and orally active *CDK9* inhibitor with an IC₅₀ of 5.5 nM. CDK9-IN-40 shows high selectivity for *CDK9* versus CDK1, CDK2, CDK4, and CDK6, respectively. CDK9-IN-40 can arrest cell cycle, induce cell apoptosis and inhibit tumor growth. CDK9-IN-40 exhibits strong anti-cancer activity .

HY-16559A

Riviciclib P276-00 free base	CDK	Cancer
Riviciclib (P276-00 free base) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits *CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB* with IC₅₀s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib shows antitumor activity on cisplatin-resistant cells .

HY-112450

Olomoucine II	CDK	Cancer
Olomoucine II is a potent *CDK* inhibitor with IC₅₀ values of 0.06, 0.1, 0.45, 7.6, 19.8 µM for CDK9/cyclin T, CDK2/cyclin E, CDK7/cyclin H, CDK1/cyclin B, CDK4/cyclin D1, respectively. Olomoucine II shows antiproliferative activity .

HY-12843

Bohemine 1 Publications Verification	CDK ERK	Cancer
Bohemine is a purine analogue and is a synthetic and selective *CDK* inhibitor with IC₅₀s of 4.6 μM, 83 μM, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively. Bohemine also inhibits ERK2 with an IC₅₀ of 52 μM and has less inhibitory effect on CDK1, CDK4 and CDK6. Bohemine has a broad spectrum anti-cancer activities .

HY-177780

Cyclin K degrader 2	Molecular Glues CDK Apoptosis	Cancer
Cyclin K degrader 2 is a molecular glucose degrading agent that targets the cyclin K protein. Cyclin K degrader 2 has inhibitory activity against *CDK1* and *CDK9. Cyclin K degrader 2 causes a decrease in RNA polymerase II Ser2 phosphorylation levels, downregulation of DNA damage response gene expression, accumulation of DNA damage, G1 phase arrest of the cell cycle, and apoptosis*. Cyclin K degrader 2 can be used for cancer research .

HY-178499

CDK9-IN-44	CDK c-Myc Bcl-2 Family	Neurological Disease Cancer
CDK9-IN-44 (Compound 7) is a selective *CDK9* inhibitor (IC₅₀=7.6 μM). CDK9-IN-44 inhibits CDK9/cyclin T1 kinase activity, blocking transcriptional elongation, reducing the expression of pro-cancer proteins (such as MCL1, c-MYC), and inducing tumor cell apoptosis. CDK9-IN-44 is promising for research of glioblastoma (GBM) and central nervous system (CNS) disorders .

HY-156296

CDK9-Cyclin T1 PPI-IN-1	CDK Apoptosis	Cancer
CDK9-Cyclin T1 PPI-IN-1 (Compound B19) is a selective CDK9-Cyclin T1 protein-protein interaction (PPI) inhibitor. CDK9-Cyclin T1 PPI-IN-1 inhibits cell proliferation in TNBC MDA-MB-231 cells (IC₅₀: 0.044 μM), and induces apoptosis. CDK9-Cyclin T1 PPI-IN-1 inhibits CDK9 transcription activity, reduces the phosphorylation of RNA Pol II CTD ser2. CDK9-Cyclin T1 PPI-IN-1 inhibits tumor growth in a TNBC 4T1 mouse model .

HY-176451

CDK9 degrader-1	CDK	Cancer
CDK9 degrader-1 (Compound AZ-9) is a selective *CDK9* degrader (DC₅₀: 0.4073 µM). CDK9 degrader-1 recruits ATG101 to initiate the autophagy-lysosome pathway and forms autophagosomes by recruiting LC3, which then fuses with lysosomes to degrade CDK9 and its partner protein Cyclin T1 (DC₅₀: 1.215 µM). CDK9 degrader-1 induces caspase 3-mediated apoptosis. CDK9 degrader-1 has antitumor activity in a mouse HCT116 xenograft model .

HY-137478B

KB-0742 hydrochloride	CDK	Cancer
KB-0742 hydrochloride is a potent, selective and orally active *CDK9* inhibitor with an IC₅₀ of 6 nM for CDK9/cyclin T1. KB-0742 hydrochloride is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 hydrochloride has potent anti-tumor activity .

HY-168892

LC3B recruiter 2	Atg8/LC3 Autophagy	Cancer
LC3B recruiter 2 (34R) is an LC3B recruiter and a component of the autophagy-lysosome pathway degradation system (ATTEC, Autophagy-Tethering Compounds), which directly binds to LC3B. LC3B recruiter 2 binds to *CDK9* inhibitor SNS-032 (HY-10008) through a linker, forming an ATTEC that targets the degradation of the *CDK9* and Cyclin T1 complex (with inhibitory effects on both). Therefore, LC3B recruiter 2 exerts activity through the LC3B-dependent autophagy-lysosome pathway, interfering with the cell cycle of cancer cells, thus exhibiting antitumor activity .

HY-153221

QR-6401	CDK	Cancer
QR-6401 is an orally active and selective macrocyclic *CDK2* inhibitor with IC₅₀ values of 0.37, 10, 22, 34 and 45 nM for *CDK2/E1, CDK9/T1, CDK1/A2, CDK6/D3* and *CDK4/D1, respectively. QR-6401 has potent antitumor activity* in an OVCAR3 ovarian cancer xenograft model. QR-6401 has the potential to be used in the study of cancer .

HY-178862

CDK9 ligand-Linker Conjugate	Target Protein Ligand-Linker Conjugates	Cancer
CDK9 ligand-Linker Conjugate is a synthesized CDK9 ligand-linker conjugate that can be used for synthesis of dCDK9-202 (HY-178861). dCDK9-202 is a potent CDK9 PROTAC degrader with anti-tumor activity .

HY-147905

CDK9-IN-18	CDK Apoptosis	Cancer
CDK9-IN-18 is a potent *CDK9* inhibitor. CDK9-IN-18 blocks the phosphorylation function of kinase CDK9. CDK9-IN-18 exhibits both good anticancer activity and low cellular activity. CDK9-IN-18 induces apoptosis.

HY-151436

ZLMT-12	CDK Cholinesterase (ChE) Apoptosis	Cancer
ZLMT-12 (compound 35), tacrine derivatives, is a potent, orally active *CDK2/9* inhibitor with IC₅₀ values of 0.002 and 0.011 μM for CDK9 and CDK2, respectively. ZLMT-12 has a weak inhibitory effect on AChE (IC₅₀=19.023 μM) and BChE (IC₅₀=2.768 μM). ZLMT-12 has low toxicity and antiproliferative activity. ZLMT-12 induces apoptosis and arrests the cell cycle in the S phase and G2/M phase .

HY-162619

CDK9-IN-33	Apoptosis CDK	Cancer
CDK9-IN-33 (compound C35) is a potent, selective and orally active *CDK9* inhibitor with IC₅₀ values of 17.44, 160, 316.30, 1771.00, >10000 nM for CDK9, CDK7, CDK2, CDK4, CDK6 respectively. CDK9-IN-33 induces apoptosis. CDK9-IN-33 decreases the protein expression of RPB1 CTD Ser2, RPB1, MCL1. CDK9-IN-33 shows anti-tumor activity .

HY-150562

CDK9-IN-19	CDK	Cancer
CDK9-IN-19 is a highly potent and selective *CDK9* inhibitor with an IC₅₀ value of 2.0 nM. CDK9-IN-19 has excellent cellular antiproliferative activity, moderate pharmacokinetic property and low hERG inhibition. CDK9-IN-19 significantly induces tumour growth inhibition in an MV4-11 xenograft mice model. CDK9-IN-19 can be used for researching acute myeloid leukaemia (AML) .

HY-156083

CDK9-IN-28	CDK	Cancer
PROTAC CDK9/CycT1 Degrader-1 (compounds 10) is a potent inhibitor of *CDK9. PROTAC CDK9/CycT1* Degrader-1 can be used as a PROTAC target protein ligand for PROTAC synthesis. PROTAC CDK9/CycT1 Degrader-1 shows strong anti-proliferative activity in solid tumors .

HY-164619

CDK9-IN-34	CDK SARS-CoV	Infection Cancer
CDK9-IN-34 (Compound 1b) is an inhibitor for *CDK9* with an IC₅₀ of 0.25 μM. CDK9-IN-34 exhibits cytotoxicity to cancer cell HCT116, MCF7 and K652 with IC₅₀s of 1.43, 3.01 and 50.27 μM, respectively. CDK9-IN-34 exhibits antiviral activity against coronavirus 229E with an IC₅₀ of 145.92 μM .

HY-155843

CDK9-IN-25	CDK SARS-CoV Virus Protease	Infection
CDK9-IN-25 (compound 4a) is an imidazopyrazine CDK9 inhibitor (IC₅₀: 0.24 μM). CDK9-IN-25 has good affinity to the main protease of COVID-19 and has antiviral activity against human coronavirus 229E (IC₅₀: 63.28 μM) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CDK9 activity

Inhibitors & Agonists